Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
|Articles|October 25, 2017
ABEC Develops Single-Use Bioreactor for Emergent Manufacturing Facility
Author(s)BioPharm International Editors
ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility.
Advertisement
On Oct. 24, 2017, ABEC, a provider of engineering, equipment, and services to the biopharmaceutical manufacturing sector, announced that Emergent BioSolutions, a provider of contract manufacturing services, will equip its bulk manufacturing facility in Bayview, Baltimore, MD, with an ABEC 4,000-L custom single run (CSR) bioreactor.
The 4,000-L bioreactor will be designed specifically for Emergent’s process needs, operational requirements, and facility constraints, and will expand cell culture capacity at the Bayview site. The system can also deliver performance comparable to stainless steel systems, can be customized for different products, and is anticipated to improve cell culture productivity, process transfer, and scale-up, according to ABEC.
“ABEC’s CSR enables us to fully realize the benefits of single-use technology by improving flexibility while leveraging economies of scale,” said Scott Battist, Emergent BioSolutions’ vice president and general manager of the Bayview site, in a company press release.
Source:
Advertisement
Related to this article
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
5